TG Therapeutics Submits Biologics License Application to the US Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

TG Therapeutics, Inc. announced the submission of a Biologics License Application to the FDA requesting approval of ublituximab, the company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis.
[TG Therapeutics, Inc.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Cellular and Humoral Immune Responses Following SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis on Anti-CD20 Therapy

The authors investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis on anti-CD20 antibody monotherapy compared with healthy controls after BNT162b2 or mRNA-1273 mRNA vaccination.
[Nature Medicine]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

US FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

BeiGene, Ltd. announced that BRUKINSA® (zanubrutinib) has received accelerated approval from the US FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen.
[BeiGene, Ltd.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

B Cell Depletion with Anti-CD20 mAb Exacerbates Anti-donor CD4+ T Cell Responses in Highly Sensitized Transplant Recipients

Scientists investigated the impact of pretransplant desensitization with rituximab on anti-donor T cell responses in donor-specific anti-human leukocyte antigen antibody-positive transplant recipients.
[Scientific Reports]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Bortezomib and Rituximab in De Novo Adolescent/Adult CD20-Positive, Ph-Negative Pre-B-Cell Acute Lymphoblastic Leukemia

The authors conducted a Phase II study to test the activity of bortezomib and rituximab in combination with a pediatric-inspired regimen during induction therapy in newly diagnosed adolescents and adults with CD20+, Philadelphia-negative precursor B-ALL; bone marrow measurable residual disease negativity at the end of induction was the primary end point.
[Blood Advances]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Bortezomib and Rituximab in De-Novo Adolescent/Adult CD20-Positive, Ph-Negative Pre B-Cell Acute Lymphoblastic Leukemia

Researchers conducted a Phase II study to test the activity of bortezomib and rituximab in combination with a pediatric-inspired regimen during induction therapy in newly diagnosed adolescents and adults with CD20-positive, Philadelphia (Ph)-negative precursor B-cell acute lymphoblastic leukemia.
[Blood Advances]
[zotpress userid=’7992332′ items=’5XGDK8BI’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Polymeric Nanomedicines Targeting Hematological Malignancies

Scientists highlight recent advance in targeted polymeric nanoformulations that are coated with varying ligands and loaded with different therapeutic agents for directing to distinct targets in hematological malignancies.
[Journal of Controlled Release]
[zotpress userid=” items=’MSQGHQXL’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

A Functional Mammalian Display Screen Identifies Rare Antibodies That Stimulate NK Cell–Mediated Cytotoxicity

To advance the development of natural killer (NK)-based therapies, scientists developed a functional screen to rapidly identify antibodies that can activate NK cells. They displayed antibodies on a mammalian target cell line and probed their ability to stimulate NK cell-mediated cytotoxicity.
[Proceedings of the National Academy of Sciences of the United States of America]
[zotpress userid=” items=’3LLCJ79L’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Immune Cell Analyses of the Tumor Microenvironment in Prostate Cancer Highlight Infiltrating Regulatory T Cells and Macrophages as Adverse Prognostic Factors

The authors characterized and assessed the prognostic potential of distinct immune cell infiltration patterns in the prostate tumor microenvironment.
[Journal of Pathology]
[zotpress userid=’6445218′ items=’B49T6FX7′ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tafasitamab combined with the immunomodulatory drug lenalidomide was clinically active with a good tolerability profile in the open-label, single-arm, phase II L-MIND study of autologous stem-cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.
[Haematologica]
[zotpress userid=’7992332′ items=’WQ5L3HMT’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

A Reasoned Approach to the Treatment of Autoimmune Hepatitis

Autoimmune hepatitis is a chronic inflammatory liver disease affecting all ages, characterized by elevated transaminase and immunoglobulin G levels, positive autoantibodies, interface hepatitis on histology and good response to immunosuppressive treatment.
[Digestive and Liver Disease]
[zotpress userid=” items=’QAV6BBCH’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share